Literature DB >> 16741941

Transmission distortion of BDNF variants to bipolar disorder type I patients from a South American population isolate.

Barbara Kremeyer1, Ibi Herzberg, Jenny Garcia, Emily Kerr, Constanza Duque, Vicky Parra, Jorge Vega, Carlos Lopez, Carlos Palacio, Gabriel Bedoya, Jorge Ospina, Andres Ruiz-Linares.   

Abstract

Recent reports have implicated polymorphisms in the brain derived neurotrophic factor (BDNF) gene region in the etiology of several psychiatric phenotypes, including bipolar disorder. Significant disease association has been reported for the G allele at SNP rs6265, which encodes for Valine at position 66 of BDNF (Val66Met), an apparently functional variant of this key BDNF. Here we examined a sample of 224 bipolar type I patients and available parents (comprising a total of 212 nuclear families) ascertained in a South American population isolate (Antioquia, Colombia). We tested for transmission distortion to bipolar patients of alleles at the rs6265 polymorphism and at a microsatellite marker 1.3 kb away from this SNP. Significant excess transmission of the rs6265 G allele to cases was observed (chi(2) = 10.77, d.f. = 1, P = 0.001). Two-locus haplotype analysis showed a significant global transmission distortion (chi(2) = 16.059, d.f. = 7, P = 0.025) with an excess transmission of a haplotype comprising the rs6265 G allele and microsatellite allele 227. These results are consistent with previous studies pointing to a role for BDNF in susceptibility to mood disorders. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16741941     DOI: 10.1002/ajmg.b.30354

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  7 in total

Review 1.  BDNF function as a potential mediator of bipolar disorder and post-traumatic stress disorder comorbidity.

Authors:  J J Rakofsky; K J Ressler; B W Dunlop
Journal:  Mol Psychiatry       Date:  2011-09-20       Impact factor: 15.992

2.  Using linkage information to weight a genome-wide association of bipolar disorder.

Authors:  D P Howrigan; N M Laird; J W Smoller; B Devlin; M B McQueen
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2011-04-07       Impact factor: 3.568

3.  Polymorphisms in melatonin synthesis pathways: possible influences on depression.

Authors:  Daniel F Kripke; Caroline M Nievergelt; Greg J Tranah; Sarah S Murray; Michael J McCarthy; Katharine M Rex; Neeta Parimi; John R Kelsoe
Journal:  J Circadian Rhythms       Date:  2011-08-09

4.  Neurotrophic tyrosine kinase receptor type 2 (NTRK2) gene associated with treatment response to mood stabilizers in patients with bipolar I disorder.

Authors:  Zuowei Wang; Jinbo Fan; Keming Gao; Zezhi Li; Zhenghui Yi; Lingxiao Wang; Jia Huang; Chengmei Yuan; Wu Hong; Shunying Yu; Yiru Fang
Journal:  J Mol Neurosci       Date:  2013-01-15       Impact factor: 3.444

Review 5.  Pharmacological treatment of bipolar disorder among children and adolescents.

Authors:  Joseph C Blader; Vivian Kafantaris
Journal:  Expert Rev Neurother       Date:  2007-03       Impact factor: 4.618

Review 6.  Evidence for single nucleotide polymorphisms and their association with bipolar disorder.

Authors:  Aleksandra Szczepankiewicz
Journal:  Neuropsychiatr Dis Treat       Date:  2013-10-11       Impact factor: 2.570

7.  Towards the clinical implementation of pharmacogenetics in bipolar disorder.

Authors:  Naji C Salloum; Michael J McCarthy; Susan G Leckband; John R Kelsoe
Journal:  BMC Med       Date:  2014-05-30       Impact factor: 8.775

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.